JP2018520205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520205A5 JP2018520205A5 JP2018511323A JP2018511323A JP2018520205A5 JP 2018520205 A5 JP2018520205 A5 JP 2018520205A5 JP 2018511323 A JP2018511323 A JP 2018511323A JP 2018511323 A JP2018511323 A JP 2018511323A JP 2018520205 A5 JP2018520205 A5 JP 2018520205A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound represented
- crystalline form
- mesylate salt
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000002904 solvent Substances 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 4
- 150000002825 nitriles Chemical class 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 238000002425 crystallisation Methods 0.000 claims 3
- 230000008025 crystallization Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- 239000003560 cancer drug Substances 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 150000001793 charged compounds Chemical class 0.000 claims 1
- 150000004292 cyclic ethers Chemical class 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510263300.3 | 2015-05-21 | ||
| CN201510263300 | 2015-05-21 | ||
| PCT/CN2016/085360 WO2016184436A1 (zh) | 2015-05-21 | 2016-06-08 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520205A JP2018520205A (ja) | 2018-07-26 |
| JP2018520205A5 true JP2018520205A5 (enExample) | 2018-09-06 |
Family
ID=57319484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511323A Pending JP2018520205A (ja) | 2015-05-21 | 2016-06-08 | レンバチニブメシル酸塩の新規結晶形及びその製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10246418B2 (enExample) |
| EP (1) | EP3287444A4 (enExample) |
| JP (1) | JP2018520205A (enExample) |
| CN (2) | CN107848979A (enExample) |
| IL (1) | IL255738A (enExample) |
| MX (1) | MX2017014799A (enExample) |
| WO (1) | WO2016184436A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6524220B2 (ja) | 2014-09-30 | 2019-06-05 | エルジー・ケム・リミテッド | ブロック共重合体 |
| US10562855B2 (en) * | 2016-06-08 | 2020-02-18 | Crystal Pharmatech Co., Ltd. | Crystalline form of lenvantinib mesylate and process of preparation thereof |
| CN110248660A (zh) * | 2016-12-29 | 2019-09-17 | 雷迪博士实验室有限公司 | 甲磺酸乐伐替尼的固态形式 |
| CN110494423B (zh) * | 2017-04-25 | 2022-04-26 | 苏州科睿思制药有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
| WO2019111283A1 (en) * | 2017-12-09 | 2019-06-13 | Msn Laboratories Private Limited, R&D Center | Novel polymorphs of 4-[3-chloro-4-(n'-cyclopropyl ureido)phenoxy]-7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof |
| CN109988112A (zh) * | 2017-12-29 | 2019-07-09 | 四川科伦药物研究院有限公司 | 仑伐替尼甲磺酸盐的晶型及其制备方法 |
| CN112204011A (zh) * | 2018-06-01 | 2021-01-08 | 成都苑东生物制药股份有限公司 | 一种甲磺酸乐伐替尼新晶型及其制备方法 |
| CN110818634B (zh) * | 2018-08-13 | 2021-11-30 | 上海新礼泰药业有限公司 | 甲磺酸乐伐替尼的精制方法 |
| EP3620453A1 (en) | 2018-09-07 | 2020-03-11 | Indena S.p.A. | New crystal form of lenvatinib |
| CN111574359A (zh) * | 2019-02-19 | 2020-08-25 | 愈磐生物科技（苏州）有限公司 | 乐伐替尼-没食子酸共晶晶型及其应用 |
| CN111689897B (zh) * | 2019-03-13 | 2024-02-06 | 齐鲁制药有限公司 | 一种高纯度甲磺酸乐伐替尼晶型c的制备方法 |
| CN109867626A (zh) * | 2019-04-18 | 2019-06-11 | 安礼特（上海）医药科技有限公司 | 一种甲磺酸仑伐替尼多晶型物及其制备方法 |
| CN110229103A (zh) * | 2019-06-27 | 2019-09-13 | 尚科生物医药（上海）有限公司 | 一种乐伐替尼甲磺酸盐晶型b的制备方法 |
| CN112174886A (zh) * | 2019-07-02 | 2021-01-05 | 成都苑东生物制药股份有限公司 | 一种甲磺酸乐伐替尼晶型x的制备方法 |
| CN114867477B (zh) * | 2019-07-08 | 2024-12-27 | 雷佐鲁特公司 | 血浆激肽释放酶抑制剂的晶型 |
| CN110563644A (zh) * | 2019-10-30 | 2019-12-13 | 北京赛思源生物医药技术有限公司 | 一种仑伐替尼甲磺酸盐的新晶型 |
| US11059787B2 (en) | 2019-11-12 | 2021-07-13 | Shenzhen Bolan Pharmaceutical Co., Ltd | Crystalline form of lenvatinib mesylate and methods thereof |
| CN113135853A (zh) * | 2020-01-19 | 2021-07-20 | 重庆医药工业研究院有限责任公司 | 一种氟伐替尼或甲磺酸盐的晶型及其制备方法 |
| JP7466642B2 (ja) * | 2020-04-24 | 2024-04-12 | 成都苑東生物制薬股▲フン▼有限公司 | レンバチニブメシル酸塩結晶形ｘｉ及びその調製方法 |
| CN112939859B (zh) * | 2021-02-03 | 2022-03-11 | 南京方生和医药科技有限公司 | 甲磺酸仑伐替尼m晶型的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| JP4648835B2 (ja) | 2003-12-25 | 2011-03-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法 |
| EP1797881B1 (en) * | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| CA2606719C (en) * | 2005-06-23 | 2010-08-10 | Eisai R & D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
| AU2010285740C1 (en) * | 2009-08-19 | 2016-03-17 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
-
2016
- 2016-06-08 US US15/575,352 patent/US10246418B2/en active Active
- 2016-06-08 WO PCT/CN2016/085360 patent/WO2016184436A1/zh not_active Ceased
- 2016-06-08 JP JP2018511323A patent/JP2018520205A/ja active Pending
- 2016-06-08 CN CN201680036277.7A patent/CN107848979A/zh active Pending
- 2016-06-08 EP EP16795923.8A patent/EP3287444A4/en not_active Withdrawn
- 2016-06-08 CN CN202110477564.4A patent/CN113527203B/zh active Active
- 2016-06-08 MX MX2017014799A patent/MX2017014799A/es unknown
-
2017
- 2017-11-19 IL IL255738A patent/IL255738A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520205A5 (enExample) | ||
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2015078199A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| JP2013543867A5 (enExample) | ||
| RU2015100280A (ru) | Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи | |
| JP2016128501A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| RU2017115925A (ru) | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе | |
| RU2018145948A (ru) | Кристалл пирролопиримидина для получения jak-ингибитора | |
| JP2015010091A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| CN110088088A (zh) | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 | |
| TN2015000367A1 (fr) | Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HRP20241280T1 (hr) | Kruti oblici rukapariba i soli rukapariba | |
| JP2019520321A5 (enExample) | ||
| JP2015516425A5 (enExample) | ||
| CN109563059A (zh) | 奥扎莫德的晶型及其制备方法 | |
| JP2013523623A5 (enExample) | ||
| RU2015130602A (ru) | Соли и кристаллические формы | |
| RU2017134709A (ru) | П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения | |
| WO2016103262A3 (en) | Crystal forms of apomorphine and uses thereof | |
| JP2017535510A5 (enExample) | ||
| JP2011515421A5 (enExample) |